RB基因缺乏的乳腺癌患者更适合接受新辅助化疗_科研在线_抗癌健康网 - 澳门巴黎人娱乐平台
欢迎来到抗癌健康网!  
放入收藏夹 | 返回首页

澳门巴黎人娱乐平台

2018-07-06

抗癌健康网

手机看网页

导读:缺乏一种被称作视网膜母细胞瘤基因(retinoblastoma, RB)的肿瘤抑制基因的乳腺癌患者对新辅助化疗(neoadjuvant chemotherapy)作出更好的反应。

根据一项于2012年7月18日在线发表在Clinical Cancer Research期刊上的回顾性研究,来自美国托马斯杰斐逊大学医院和基梅尔癌症中心的研究人员报道,缺乏一种被称作视网膜母细胞瘤基因(retinoblastoma, RB)的肿瘤抑制基因的乳腺癌患者对新辅助化疗(neoadjuvant chemotherapy)作出更好的反应。

在这项研究中,研究人员对1000多名接受过新辅助疗法(neoadjuvant therapy)的乳腺癌患者开展基因表达谱分析来鉴定那些缺乏基因RB的病人,同时还进行直接组织学分析。这些病人代表着不同的乳腺癌亚型,并接受不同用药方案的澳门巴黎人娱乐平台。

研究人员发现基因RB缺失与大多数乳腺癌亚型对所有已研究的新辅助疗法的反应发生改善相关联。

总之,这些数据表明基因RB缺失可能是一种有用的生物分子标记物来确定对新辅助化疗作出更好反应的乳腺癌患者。基因这些发现,研究人员已启动一项前瞻性的临床试验以便评估RB和另一种分子标记物PTEN与乳腺癌对新辅助化疗作出的反应之间存在的关联性。(生物谷:Bioon.com)

本文编译自Breast cancer patients who lack RB gene respond better to neoadjuvant chemotherapy

doi: 10.1158/1078-0432.CCR-12-0903
PMC:
PMID:

RB-pathway Disruption is Associated with Improved Response to Neoadjuvant Chemotherapy in Breast Cancer

Agnieszka K. Witkiewicz1,*, Adam Ertel2, Jeanne M. McFalls3, Matias E Valsecchi4, Gordon Schwartz5, and Erik S. Knudsen

Purpose: We sought to determine whether dysregulation of the RB tumor suppressor pathway was associated with improved response to neoadjuvant chemotherapy in breast cancer. Experimental Design: An RB-loss signature was used to analyze the association between pathway status and pathological complete response in gene expression datasets encompassing three different neoadjuvant regimens. Parallel immunohistochemical analysis of the RB-pathway was performed on pretreatment biopsies to determine the association with pathological response to neoadjuvant chemotherapy. Results: An RB loss gene expression signature was asssociated with increased pathological complete response in datasets from breast cancer patients treated neoadjuvant therapy encompasssing approximately 1,000 patients. The association with improved response to neoadjuvant chemotherapy was true in both ER-positive and ER-negative breast cancer. Elevated expression of p16ink4a is associated with the RB-loss of signature (R=0.493-0.5982), and p16ink4a mRNA levels were strongly associated with pathological complete response. In an independent cohort, immunohistochemical analyses of RB and p16ink4a revealed an association of RB loss (p=0.0018) or elevated p16ink4a (p=0.0253) with pathological complete response. Additionally, by Miller-Payne and Clinical-Pathologic Scoring (CPS) analyses, RB-deficient tumors experienced an overall improved response to neoadjuvant chemotherapy. Conclusion: Disruption of the RB-pathway as measured by several independent methods was associated with improved response to neoadjuvant chemotherapy. The RB-pathway status was relevant for pathological response in both ER-positive and ER-negative breast cancer with similar results observed with multiple chemotherapy regimens. Combined, these data indicate that RB-status is associated with the response to neoadjuvant chemotherapy in breast cancer and could be employed to inform treatment.

在这里,掌握健康资讯

扫描左侧二维码即可添加抗癌健康网官方微信;
健康之路 与你同行
乳腺癌更多>>
乳腺癌是女性最常见的恶性肿瘤之一,发病率占全身各种恶性肿瘤的7-10%,已成为威胁妇女健康的主要病因。[详情]
热文欣赏更多>>

健康阅读

推荐欣赏

  • 热门推荐
  • 最新期刊
  • 疾病关注
长期憋尿,膀胱癌,长期憋尿引发膀胱癌
[详情]
白血病与骨髓移植术
[详情]
筷子致癌?靠什么吃饭?
[详情]
卵巢囊肿并不可怕
[详情]
调理内分泌多吃黄色食物
[详情]
吃腐乳致癌可信吗?
[详情]
资讯排行榜更多>>
肺癌康复指南吃什么?
信息聚焦更多>>
化疗药物中成药止痛药
卡铂复方红豆杉胶囊阿司匹林
顺铂平消片扑热息痛
吉西他滨西黄胶囊盐酸哌替啶片
卡培他滨消癌平片吗啡
希罗达至灵胶囊芬太尼
视频推荐更多>>
肿瘤热文欣赏更多>>

特别声明:本站信息仅供参考 不能作为诊断及医疗的依据平台联系我们

抗癌健康网 版权所有 未经授权请勿转载  CopyRight©2008-2018 www.latiendaespanola.com, All Rights Reserved. 浙ICP备11014848号